Literature DB >> 11595501

Telomerase in endocrine and endocrine-dependent tumors.

C Orlando1, S Gelmini.   

Abstract

Telomerase, the ribonucleoprotein enzyme that elongates chromosomal ends, or telomeres, is repressed in most normal somatic cells but reactivated in transformed cells to compensate for the progressive erosion of the telomeres during cell divisions. In accordance with this hypothesis, the presence of telomerase activity has been reported in more than 90% of human cancers, whereas most normal tissues or benign tumors contain low or undetectable telomerase activity. Reactivation of telomerase has also been widely reported in endocrine neoplasms and in hormone-related cancers. In the present study, we review the most recent publications on telomerase in these types of tumors. The hormonal regulation of telomerase activity and the possible strategies for cancer therapy based on the inhibition of telomerase has also been discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595501     DOI: 10.1016/s0960-0760(01)00101-7

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.

Authors:  Na Wang; Dawei Xu; Anastasios Sofiadis; Anders Höög; Vladana Vukojević; Martin Bäckdahl; Jan Zedenius; Catharina Larsson
Journal:  J Clin Endocrinol Metab       Date:  2014-04-23       Impact factor: 5.958

2.  Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.

Authors:  Zuojie Luo; Jianling Li; Yinfen Qin; Yan Ma; Xinghuan Liang; Jing Xian; Decheng Lu; Minyi Wei; Jack Y Yang; Mary Qu Yang; Zhiheng He
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

3.  Telomerase and estrogen-sensing activities are essential for continued mammary growth in vivo but dispensable for "reprogramming" neural stem cells.

Authors:  Andrea L George; Corinne A Boulanger; Gilbert H Smith
Journal:  Aging (Albany NY)       Date:  2016-07       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.